Recommendation for the management of dopamine agonists in ICD in Parkinson’s disease (new)
Withdrawal of dopamine agonists is an effective ICD treatment. We recommend a gradual reduction of dopamine agonist dosage In the event of adverse effects of dopamine agonist reduction (e.g. dopamine agonist withdrawal syndrome), the dopamine agonist should be reduced to the lowest tolerated dose Patients with Parkinson's disease who are eligible for continuous non-oral dopaminergic therapy may be considered for ICD therapy with levodopa-carbidopa intestinal gel (LCIG)
Level of consensus: 100%, strong consensus